Identification of an acquired mutation in Jak2 provides molecular insights into the pathogenesis of myeloproliferative disorders

Mol Interv. 2005 Aug;5(4):211-5. doi: 10.1124/mi.5.4.4.

Authors

Marko Pesu¹, John O'Shea, Lothar Hennighausen, Olli Silvennoinen

Affiliation

¹ Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA. [email protected]

PMID: 16123535
DOI: 10.1124/mi.5.4.4

No abstract available

MeSH terms

Humans
Janus Kinase 2
Models, Molecular
Myeloproliferative Disorders / genetics*
Myeloproliferative Disorders / physiopathology*
Point Mutation*
Protein Structure, Tertiary
Protein-Tyrosine Kinases / chemistry
Protein-Tyrosine Kinases / genetics*
Protein-Tyrosine Kinases / physiology*
Proto-Oncogene Proteins / chemistry
Proto-Oncogene Proteins / genetics*
Proto-Oncogene Proteins / physiology*

Substances

Proto-Oncogene Proteins
Protein-Tyrosine Kinases
JAK2 protein, human
Janus Kinase 2